

SFS PHARMA LOGISTICS PRIVATE LIMITED
ACCOUNTS
2021-2022



INDEPENDENT AUDITORS' REPORT

To the Members of SFS Pharma Logistics Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of SFS Pharma Logistics Private Limited ("the Company"), which comprise the standalone balance sheet as at 31 March 2022, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2022, and profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



To the Members of SFS Pharma Logistics Private Limited

Key Audit Matters (continued)

Description of Key Audit Matters

Revenue recognition

See note 2.6 to the standalone financial statements

The key audit matter	How the matter was addressed in our audit
<p>The Company has only one business of logistics service in India and Abroad for clinical trial shipments and pharma products.</p> <p>All expenditure which the client incur for clearance of goods in Indian ports are met by the company on behalf of the client.</p> <p>Revenue is recognised when the company completes their service as per the contract and the invoice is raised for the service charges and also for reimbursement of the expenses met by the company on behalf of the client.</p> <p>We identified revenue recognition as a key audit matter as it involves more number of transactions.</p>	<p>In view of the significance of the matter we applied the following audit procedures in this area, among others, to obtain sufficient appropriate audit evidence:</p> <ol style="list-style-type: none">1. We assessed the appropriateness of the revenue recognition accounting policies, by comparing with applicable accounting standards.2. We evaluated the management controls with respect to revenue recognition with specific focus on separate job assignments.3. We performed substantive testing by selecting samples of revenue transactions recorded during the year by verifying the underlying documents.4. We carried out analytical procedures on revenue recognised during the year to identify unusual variances.



Information Other than the Standalone Financial Statements and Auditors' Report Thereon

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors is also responsible for overseeing the Company's financial reporting process.



To the Members of SFS Pharma Logistics Private Limited

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



To the Members of SFS Pharma Logistics Private Limited

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2020 ("the Order") issued by the Central Government in terms of section 143 (11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

(A) As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
- c) The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account;
- d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under section 133 of the Act with relevant Rules issued thereunder;



Independent Auditors' Report (continued)

Report on Other Legal and Regulatory Requirements (continued)

- e) On the basis of the written representations received from the directors as on 31 March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2022 from being appointed as a director in terms of Section 164(2) of the Act;
 - f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B";
- (B) With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company does not have any pending litigations which would impact its financial position;
 - ii. The Company did not have any Long Term Contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which required to be transferred to Investor Education and Protection Fund.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person or entity, including foreign entity ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The Management has represented, that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the Company from any person or entity, including foreign entity ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.



To the Members of SFS Pharma Logistics Private Limited

- v. (a) The Company has not proposed any dividend in the previous year.
(b) The Company has not declared and paid any interim dividend during the year.
(c) The Company has not proposed any dividend during the year.

(C) With respect to the matter to be included in the Auditors' Report under section 197(16):

No directors of the company have received any remuneration from the company during the year.

for Jerry Sunny & Rajesh

Chartered Accountants

Firm registration No. 001326S



CA. Sunny Varghese

Partner

Membership No: 028612

UDIN: 22028612AIYLWG1000

Place: Ernakulam

Date: 10 May 2022



To the Members of SFS Pharma Logistics Private Limited

SFS Pharma Logistics Private Limited

Annexure - A to the Independent Auditors 'Report

The Annexure referred to in our Independent Auditors' Report to the Members of the Company on the standalone financial statements for the year ended 31 March 2022. We report that:

- i. (a) (A) The company has maintained proper records showing full particulars including quantitative details and situation of its fixed assets.

(B) The company has no intangible assets.

(b) As explained to us, fixed assets have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification and the same have been properly dealt with the books of account.

(c) There are no immovable properties whose title deeds are not held in the name of the Company

d) The Company has not revalued its property during the year.

(e) The Company is not holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and the rules made thereunder.
- ii. (a) As explained to us, the inventories were physically verified during the year by the Management at reasonable intervals and no material discrepancies were noticed on physical verification.

(b) The company has not been sanctioned any working capital loans from banks or financial institutions on the basis of security of current assets
- iii. According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties.
- iv. The Company has not given any loans, made any investments in or given any guarantees and security which may attract the provisions of section 185 and 186 of the Companies Act, 2013.
- v. The Company has not accepted any deposits from public during the year and hence the directives issued by the Reserve Bank of India and the provisions of section 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed there under are not applicable to the Company.
- vi. The Central Government has not prescribed maintenance of cost records under Section 148 (1) of the Companies Act, 2013 for the Company's products.



To the Members of SFS Pharma Logistics Private Limited

- vii. (a) According to the records of the company, all undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service Tax, Custom Duty, Excise Duty, value added tax, Goods and Service Tax, Cess to the extent applicable and any other statutory dues have generally been regularly deposited with the appropriate authorities. According to the information and explanations given to us there were no outstanding statutory dues as on 31 March 2022 for a period of more than six months from the date they became payable.
- (b) According to the information and explanations given to us, there are no amounts payable in respect of income tax or wealth tax or service tax or sales tax or customs duty or excise duty or Goods and Service Tax or cess which have not been deposited on account of any disputes.
- viii. According to the information and explanations given to us and on the basis of our examination of the books of account, the company has no transactions which are not recorded in the books of account.
- ix. Based on our audit procedures and on the information and explanations given by the management, we are of the opinion that, the Company has not defaulted in repayment of dues to any lender.
- x. (a) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised any money by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (x) of the Order are not applicable to the Company and hence not commented upon.
- (b) The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.
- xi. (a) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- (b) No report under sub-section 12 of section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) The auditor has not considered any whistle-blower complaints received during the year.
- xii. In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 3 (xii) of the Order are not applicable to the Company.



To the Members of SFS Pharma Logistics Private Limited

- xiii. In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Ind AS Financial Statements as required by the applicable accounting standards.
- xiv. The Company has an internal audit system which is commensurate with the size and nature of its business. But the company has not appointed any internal auditor as it is not mandatory as per Section 138(2) of the Companies Act, 2013 read with rules 13 of Companies (Accounts) Rules, 2014.
- xv. The company has not entered into any non-cash transactions with directors or persons connected with him and therefore the provisions of section 192 of the Companies Act is not applicable to the Company
- xvi. According to our information and knowledge, the company is not a Non Banking Financial Company hence not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934.
- xvii. The company has not incurred cash losses in the financial year and in the immediately preceding financial year.
- xviii. No resignation of statutory auditors has taken place during this year.
- xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, the auditor's knowledge of the Board of Directors and management plans, the auditor is of the opinion that no material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date
- xx. According to the information and explanations given to us and based on our examination of the records of the company, the provisions of section 135(5) will not be applicable to the company.
- xxi. Since this company has no subsidiary companies reporting under clause xxi of paragraph 3 of the order is not applicable.

for Jerry Sunny & Rajesh

Chartered Accountants

Firm registration No. 001326S



CA. Sunny Varghese

Partner

Membership No: 028612

UDIN: 22028612AIYLWG1000

Place: Ernakulam

Date: 10 May 2022



To the Members of SFS Pharma Logistics Private Limited
Annexure –B to the Independent Auditors' Report

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013
(Referred to in paragraph 1A(f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls over financial reporting of SFS Pharma Logistics Private Limited ('the Company') as of 31 March 2022 in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2022, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as "the Act").

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

Independent Auditors' Report (continued)



To the Members of SFS Pharma Logistics Private Limited

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.


Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

for **Jerry Sunny and Rajesh**

Chartered Accountants

Firm registration No. 001326S


CA. Sunny Varghese

Partner

Membership No: 028612

UDIN: 22028612AIYLBWG1000

Place: Ernakulam

Date: 10 May 2022



SFS Pharma Logistics Private Limited
Balance sheet as at 31 March 2022
(All amounts in Indian rupees)

ASSETS

Non-current assets

Property, plant and equipment

Financial assets

Other financial assets

Income tax assets (net)

Deferred tax assets (net)

Total non-current assets

Current assets

Inventories

Financial assets

Trade receivables

Cash and cash equivalents

Other financial assets

Other current assets

Total current assets

TOTAL ASSETS

EQUITY AND LIABILITIES

EQUITY

Equity share capital

Other equity

Total equity

LIABILITIES

Non-current liabilities

Deferred tax liabilities (net)

Provisions

Total non-current liabilities

Current liabilities

Financial liabilities

Borrowings

Trade payables

- Dues of micro enterprises and small enterprises

- Dues of other than micro enterprises and small enterprises

Other financial liabilities

Other current liabilities

Provisions

Total current liabilities

TOTAL EQUITY AND LIABILITIES

Significant accounting policies

The accompanying notes are an integral part of the standalone balance sheet.

As per our report of even date attached.

for **JERRY, SUNNY & RAJESH**

Chartered Accountants

ICAI Firm's Registration number: 001326S



Sunny Varghese

Partner

Membership No. : 028612

Place: Kochi

Date: 10 May 2022



Notes As at 31 March 2022 As at 31 March 2021

3 27,06,481 26,69,076

4 3,90,399 -

24 6,84,573 3,75,458

24 74,412 -

37,55,865 30,44,534

6 36,03,790 15,83,089

7 48,17,434 76,33,767

8 5,32,607 4,25,904

4 11,53,065 11,58,469

5 3,83,063 1,26,725

1,34,89,959 1,42,27,954

1,72,45,824 1,72,72,488

9 1,00,00,000 1,00,00,000

(15,74,144) (89,00,239)

84,25,856 10,99,761

24 - 2,793

10 7,82,806 5,07,480

7,82,806 5,10,273

11 13,00,000 37,00,000

12 - -

46,11,199 69,88,216

13 16,77,907 47,68,444

14 3,41,062 1,13,794

10 1,07,000 72,000

80,37,162 1,56,62,454

1,72,45,824 1,72,72,488

2

for and on behalf of the Board of Directors of

SFS Pharma Logistics Private Limited

CTIN: U63090KL2011PTC029554



Rajesh

Director

DIN: 08093860

Place: Kochi

Date: 10 May 2022



Mohan Kurian

Director

DIN: 03260152

SFS Pharma Logistics Private Limited
Statement of profit and loss for the year ended 31 March 2022
(All amounts in Indian rupees)

	Notes	Year ended 31 March 2022	Year ended 31 March 2021
Income			
Revenue from operations	15	3,85,75,106	1,93,63,312
Other income	16	1,67,675	28,593
Total income		3,86,82,241	1,93,91,906
Expenses			
Employee benefits expense	17	54,88,634	35,36,880
Finance costs	18	3,61,023	3,53,929
Depreciation expense	19	3,75,775	3,24,740
Other expenses	20	2,42,80,780	1,41,45,005
Total expenses		3,05,04,212	1,83,60,554
Profit before tax		81,78,029	10,31,352
Tax expense:	24		
Current tax		8,48,389	-
Deferred tax credit		(56,210)	(6,124)
Total tax expense/ (credit)		7,92,179	(6,124)
Profit for the year		73,85,850	10,37,476
Other comprehensive income/ (loss)			
<i>Items that will not be reclassified subsequently to statement of profit and loss</i>			
Remeasurement of defined benefit liability	25	(80,750)	44,290
Income tax related to items that will not be reclassified to profit or loss	24	20,995	(11,515)
Total other comprehensive income/ (loss) for the year, net of income tax		(59,755)	32,775
Total comprehensive income for the year		73,26,095	10,70,251
Earnings per equity share (Equity shares of face value ₹ 10 each)	21		
Basic (₹)		7.39	1.04
Diluted (₹)		7.39	1.04

Significant accounting policies

2

The accompanying notes are an integral part of the standalone statement of profit and loss

As per our report of even date attached

for JERRY, SUNNY & RAJESH
Chartered Accountants
ICAI Firm's Registration number: 001326S

for and on behalf of the Board of Directors of
SFS Pharma Logistics Private Limited
CIN: U63090KL2011PTC024554


Sunny Varghese
Partner

Membership No.: 028612

Place: Kochi
Date: 10 May 2022




Rajesh
Director
DIN: 08093860

Place: Kochi
Date: 10 May 2022


Mohan Kurian
Director
DIN: 03260152

SFS Pharma Logistics Private Limited
Statement of cash flows for the year ended 31 March 2022
(All amounts in Indian rupees)

	Year ended 31 March 2022	Year ended 31 March 2021
Cash flows from operating activities		
Profit before tax	81,78,029	10,31,362
Adjustments for:		
Depreciation expense	3,73,775	3,24,740
Finance costs	5,61,023	3,53,929
Interest income	(11,738)	(14,519)
Liabilities: provisions no longer required written back	(95,234)	(13,985)
Unrealised exchange loss: (gain) (net)	2,88,274	(67,122)
Loss on sale of property, plant and equipment (net)	-	4,418
Net impairment loss on financial and contract assets	69,848	-
Provision for inventory obsolescence	5,00,000	-
Operating profit before working capital changes	94,63,977	16,18,813
Changes in assets and liabilities		
(Increase)/ decrease in inventories	(23,20,701)	1,73,115
Decrease/ (increase) in trade receivable	24,56,370	(46,79,237)
Increase/(decrease) in other financial assets	15,005	(4,12,530)
Increase in other assets	(2,56,338)	(1,18,460)
(Decrease)/ increase in trade payables	(32,92,917)	33,80,431
Decrease in other financial liabilities	(27,67,700)	(3,77,818)
(Decrease)/ increase in other liabilities	2,07,268	(2,26,699)
Increase in provisions	2,39,576	1,03,804
Cash generated from operating activities	47,34,132	(4,38,531)
Income taxes paid, net of refund	(11,45,766)	3,77,893
Net cash from operating activities (A)	35,88,366	(1,60,638)
Cash flows from investing activities		
Purchase of property, plant and equipment	(4,11,180)	(59,802)
Proceeds from sale of property, plant and equipment	-	9,000
Net cash from investing activities (B)	(4,11,180)	(50,802)
Cash flows from financing activities		
Loan availed from holding company	-	5,00,000
Repayment of loan availed from holding company	(24,00,000)	-
Finance costs	(6,70,583)	(14,299)
Net cash used in financing activities (C)	(30,70,583)	4,55,731
Increase in cash and cash equivalents, net (A+B+C)	1,06,703	2,44,251
Cash and cash equivalents at the beginning of the year	4,25,904	1,81,653
Cash and cash equivalents at the end of the year (refer note 8)	5,32,607	4,25,904

Note. The above standalone statement of cash flows has been prepared under the 'Indirect method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Summary of significant accounting policies (refer note 2)

The accompanying notes are an integral part of the statement of cash flows

As per our report of even date attached

for **JERRY, SUNNY & RAJESH**
Chartered Accountants
ICAI Firm's Registration number: 001326S


Sunny Varghese
Partner
Membership No. 028612

Place: Kochi
Date: 10 May 2022



for and on behalf of the Board of Directors of
SFS Pharma Logistics Private Limited
CIN: U63000KL2011PTC029554


Rajesh S
Director
DIN: 08091860

Place: Kochi
Date: 10 May 2022


Mohan Kurian
Director
DIN: 03260182

SFS Pharma Logistics Private Limited
Statement of changes in equity for the year ended 31 March 2022
(All amounts in Indian rupees)

A. Equity Share Capital

Particulars	As at:			
	31 March 2022		31 March 2021	
	No. of shares	Amount	No. of shares	Amount
Balance at the beginning of the year	10,00,000	1,00,00,000	10,00,000	1,00,00,000
Changes in Equity Share Capital due to prior period errors	-	-	-	-
Restated balance at the beginning of the year	10,00,000	1,00,00,000	10,00,000	1,00,00,000
Changes in equity share capital during the year	-	-	-	-
Balance at the end of the year	10,00,000	1,00,00,000	10,00,000	1,00,00,000

B. Other Equity

Particulars	Reserves and surplus	Items of other comprehensive income	Total
	Retained earnings	Re-measurements of the net defined benefit liability, net of tax	
Balance as at 1 April 2020	(99,70,490)	-	(99,70,490)
Changes in other equity due to changes in accounting policy or prior period errors	-	-	-
Restated balance as at 1 April 2020	(99,70,490)	-	(99,70,490)
Profit for the year (net of taxes)	10,37,476	-	10,37,476
Other comprehensive income for the year (net of taxes)	-	32,775	32,775
Total comprehensive income for the year	10,37,476	32,775	10,70,251
Transferred to retained earnings	32,775	(32,775)	-
Total contributions by and distributions to owners	32,775	(32,775)	-
Balance as at 31 March 2021	(89,00,239)	-	(89,00,239)
Changes in other equity due to changes in accounting policy or prior period errors	-	-	-
Restated balance as at 1 April 2021	(89,00,239)	-	(89,00,239)
Profit for the year (net of taxes)	73,85,850	-	73,85,850
Other comprehensive loss for the year (net of taxes)	-	(59,755)	(59,755)
Total comprehensive income for the year	73,85,850	(59,755)	73,26,095
Transferred to retained earnings	(59,755)	59,755	-
Total contributions by and distributions to owners	(59,755)	59,755	-
Balance as at 31 March 2022	(15,74,144)	-	(15,74,144)

Summary of significant accounting policies (refer note 2)

The accompanying notes are an integral part of the standalone statement of changes in equity

As per our report of even date attached

for JERRY, SUNNY & RAJESH
Chartered Accountants
ICAI Firm's Registration number: 001326S



Sunny Varghese
Partner
Membership No.: 028612

Place: Kochi
Date: 10 May 2022



for and on behalf of the Board of Directors of
SFS Pharma Logistics Private Limited,
CIN: U63090KL2011PTC029554


Rajesh S.
Director
DIN: 00093860

Place: Kochi
Date: 10 May 2022


Mohan Kurian
Director
DIN: 03260352

1 Corporate information

SFS Pharma Logistics Private Limited is a wholly owned subsidiary of Aspinwall and Company Limited. The Company is engaged in the business of logistics assistance in India and abroad for clinical trial shipments and pharma products.

The Company has its registered office at Aspinwall House, T.C.No. 24/2269 (7), Kawdiar-Kuravankonam Road, Kawdiar, Thiruvananthapuram - 695003.

2 Basis of preparation and significant accounting policies

2.1 Statement of compliance

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under Section 133 of Companies Act, 2013, (the 'Act') read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

The standalone financial statements were authorised for issue by the Company's Board of Directors on 10 May 2022.

2.2 Functional and presentation currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts have been rounded-off to the nearest rupees, unless otherwise indicated.

2.3 Basis of measurement

The financial statements have been prepared on the historical cost basis except for 'net defined benefit liability' which is valued at present value of defined benefit obligations.

2.4 Use of estimates and judgements

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

i. Judgements

There are no significant judgements made in applying accounting policies that have the most material effects on the amounts recognised in the financial statements.

ii. Assumptions and estimation uncertainties

(a) Useful lives of Property, plant and equipment

Property, plant and equipment and intangible assets represent a proportion of the asset base of the Company. The charge in respect of periodic depreciation and amortisation is derived after determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful life and residual values of Company's assets are determined by Management at the time the asset is acquired and reviewed periodically, including each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life, such as changes in technology.

(b) Others

Further information about assumptions and estimation of uncertainties that have significant risk of resulting in a material adjustment for the year 31 March 2022 is included in the following notes:

Note 24 – Deferred Tax

Note 25 – measurement of defined benefit obligations: key actuarial assumptions

2.5 Measurement of fair values

A number of Company's accounting policies and disclosures require the measurement of fair values, for financial assets and liabilities.

The Company has an established frame work with respect to the measurement of fair values. This includes a finance team that has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values, and reports directly to the Director.



2.5 Measurement of fair values (Continued)

The finance team regularly reviews significant unobservable inputs and valuation adjustments. If third party information, such as interest rates, guarantee commission and pricing services are used to measure fair values, then the finance team assesses the evidence obtained from the third parties to support the conclusion that these valuation meet the requirements of Ind AS, including the level in the fair value hierarchy in which the valuation should be classified.

Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- i. Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- ii. Level 2: inputs other than quoted prices are included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- iii. Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the input used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognises transfers between the levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

2.6 Revenue recognition

i. Income from services

Incomes from services are accounted on completion of jobs.

ii. Other Income

In calculating interest income, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit impaired).

2.7 Inventories

Inventories are valued at the lower of cost and the net realisable value after providing for obsolescence and other losses, wherever considered necessary. The cost of inventory is determined on weighted average basis. Cost includes expenditure incurred in acquiring the inventories and other costs incurred in bringing them to their present location and condition including octroi and other levies, transit insurance and receiving charges. Inventory is charged to statement of profit and loss on consumption.

2.8 Property, plant and equipment

i. Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs if any, less accumulated depreciation and accumulated impairment losses, if any.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

ii. Transition to Ind AS

On transition to Ind AS, the Company has elected to continue with the carrying value of all of its property, plant and equipment recognised as at 1 April 2016, measured as per the previous GAAP, and use that carrying value as the deemed cost of such property, plant and equipment (see Note 3 on Ind AS 101).

iii. Subsequent expenditure

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.



2.8 Property, plant and equipment (Continued)

iv. Depreciation

Depreciation is provided on the cost of items of property, plant and equipment less their estimated residual values over their estimated useful lives prescribed in Schedule II to the Companies Act, 2013 using the Straight Line Method ('SLM').

Depreciation on additions during the year is provided for on a pro-rata basis i.e. from the date on which asset is acquired. Depreciation on disposals is provided on a pro-rata basis i.e. upto the date on which asset is disposed off.

2.9 Financial Instruments

i. Recognition and initial measurement

Trade receivables are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

The Company measures a financial asset or a financial liability at its fair value. In the case of a financial asset or a financial liability measured not at fair value through profit or loss, the transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability are adjusted in the value of the financial asset or financial liability.

ii. Classification and subsequent measurement

(a) Financial assets

On initial recognition, a financial asset is classified as measured at:

- Amortised cost; or
- Fair value through other comprehensive income (FVOCI)
- Fair value through profit and loss (FVTPL)

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment losses are recognised in profit or loss. Any gain or loss on derecognition is recognised in profit or loss. A financial asset is subsequently measured at FVOCI if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. These assets are subsequently measured at fair value. Interest income under the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognised in OCI. On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss.

All financial assets not classified as measured at amortised cost or FVOCI are measured at FVTPL. This includes all derivative financial assets. These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in profit or loss.

(b) Financial liabilities: Classification, subsequent measurement and gains and losses:

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified at FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in profit or loss. Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in profit or loss. Any gain or loss on derecognition is also recognised in profit or loss.

iii. Derecognition

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109. A financial liability (or a part of a financial liability) is derecognised from the Company's balance sheet when the obligation specified in the contract is discharged or cancelled or expires.



2.9 Financial Instruments (Continued)

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

v. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issuance of new ordinary shares and share options are recognised as a deduction from equity, net of any tax effects.

2.10 Employee benefits

Employee benefits include short-term employee benefits, provident fund, superannuation fund, gratuity and compensated absences.

i. Short-term employee benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service provided. A liability is recognised for the amount expected to be paid e.g., under short-term cash bonus, if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the amount of obligation can be estimated reliably. These benefits include performance incentive and compensated absences which are expected to occur within twelve months after the end of the period in which the employee renders the related service.

ii. Post employment benefits

(a) Gratuity

The Company has an obligation towards gratuity, a defined retirement benefit covering all eligible employees. It provides for a lump sum payment to vested employees as per the Payment of Gratuity Act, 1972 and is payable on the exit of the employees after completion of at least five years of service. However any exit due to death or total disability to do any gainful employment, this service minimum is ignored. The present value of this defined benefit obligation and the related current service cost are measured, using the Projected Unit Credit Method, by actuarial valuation at the balance sheet date and provided.

(b) Provident Fund

The eligible employees of the Company are entitled to receive benefits under the Employees' Provident Funds and Miscellaneous Provisions Act, 1952, a defined contribution plan, in which both employees and the Company make fixed contributions at a specified percentage of the covered employees' salary (currently 12% of employees' salary).

(c) Superannuation

The Company makes contributions equal to a specified percentage of the covered employee's basic salary and DA, to a fund managed by the Life Insurance Corporation of India (LIC). The Company has no further obligations beyond its contributions.

iii. Other long-term employee benefits

All employee benefits (other than post-employment benefits and termination benefits) which do not fall due wholly within twelve months after the end of the period in which the employees render the related services are determined based on actuarial valuation or discounted present value method carried out at each balance sheet date. The expected cost of accumulated compensated absences is determined by actuarial valuation performed by an independent actuary as at 31 March every year using projected unit credit method on the additional amount expected to be paid / availed as a result of the unused entitlement that has accumulated at the balance sheet date.

2.11 Taxation

i. Current Tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset or settle the liability on a net basis or simultaneously.



2.11 Taxation (Continued)

ii. Minimum Alternate Tax (MAT)

MAT paid in accordance with provisions of Income Tax Act, 1961 which gives rise to future economic benefits in the form of adjustment of future Income Tax liability, is being absorbed in the Statement of Profit and Loss and the credit is being recognised when it is probable that the future economic benefit associated with it will flow to the Company.

iii. Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding amounts used for taxation purposes. Deferred tax is also recognised in respect of carried forward tax losses and tax credits.

Deferred tax assets are recognised to the extent it is probable that future taxable profits will be available against which they can be used. The existence of unused tax losses is a strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that there is convincing evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date.

The measurement of deferred tax reflects the tax consequences that would follow in the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different taxable entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

2.12 Earnings per share (EPS)

Basic earnings per share ('EPS') is computed by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of shares outstanding during the year.

Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the period except where the result would be anti-dilutive.

2.13 Cash flow statement

Cash flows are reported using the indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

2.14 Cash and cash equivalents

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term balances (with an original maturity period of three months or less from the date of acquisition) that are readily convertible into known amounts of cash.

2.15 Operating Cycle

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

2.16 Goods and Service Tax ('GST') input credit

GST input credit is accounted for in the books in the period in which the underlying goods or service received is accounted and when there is reasonable certainty in availing / utilising the credits.



SFS Pharma Logistics Private Limited
Notes to the financial statements for the year ended 31 March 2022 (Continued)

(All amounts in Indian rupees)

3 Property, plant and equipment

Particulars	Plant and equipment	Furniture and fixtures	Office equipments	Total
Cost or deemed cost				
Balance as at 1 April 2020	3,033,179	531,708	319,240	3,884,127
Additions	-	-	59,802	59,802
Deletions	(22,031)	-	-	(22,031)
Balance as at 31 March 2021	3,011,148	531,708	379,042	3,921,898
Balance as at 1 April 2021	3,011,148	531,708	379,042	3,921,898
Additions	295,000	-	116,180	411,180
Deletions	-	-	-	-
Balance as at 31 March 2022	3,306,148	531,708	495,222	4,333,078
Accumulated depreciation				
Balance as at 1 April 2020	(813,370)	(51,537)	(71,788)	(936,695)
Depreciation for the year	(206,222)	(53,497)	(65,021)	(324,740)
Deletion	8,613	-	-	8,613
Balance as at 31 March 2021	(1,010,979)	(105,034)	(136,809)	(1,252,822)
Balance as at 1 April 2021	(1,010,979)	(105,034)	(136,809)	(1,252,822)
Depreciation for the year	(218,264)	(52,546)	(102,965)	(373,775)
Deletion	-	-	-	-
Balance as at 31 March 2022	(1,229,243)	(157,580)	(239,774)	(1,626,597)
Net carrying amount				
As at 31 March 2021	2,000,169	426,674	242,233	2,669,076
As at 31 March 2022	2,076,905	374,128	255,448	2,706,481

Notes:

a. The company has not revalued its Property, plant and equipment during the current year and previous year.

b. There are no immovable properties whose title deeds are not held in the name of the Company as at 31 March 2022 and 31 March 2021.

4 Other financial assets
Non-current
Unsecured, considered good

Employee advances

	As at 31 March 2022	As at 31 March 2021
--	------------------------	------------------------

290,399

-

290,399
-
Current
Unsecured, considered good

Security Deposits

221,870

215,000

Employee advances

108,206

21,295

Contractually reimbursable expenses

3,822,989

4,222,174

Unsecured, considered credit impaired

Contractually reimbursable expenses

30,669

-

4,183,734

4,458,469

(30,669)

-

Provision for credit impaired contractually reimbursable expenses

4,153,065
4,458,469
5 Other assets
Current
Unsecured, considered good

Jobs in progress

373,676

119,225

Contract assets/ Advance to contractors

9,387

7,500

383,063
126,725


SFS Pharma Logistics Private Limited
Notes to the financial statements for the year ended 31 March 2022 (Continued)
(All amounts in Indian rupees)

	As at 31 March 2022	As at 31 March 2021
6 Inventories (at lower of cost and net realisable value)		
Stores and spares (Packing materials)	3,903,790	1,583,089
Provision for obsolescence	(300,000)	-
	<u>3,603,790</u>	<u>1,583,089</u>
7 Trade receivables		
Unsecured, considered good	4,817,434	7,633,767
Unsecured, having significant increase in credit risk	17,067	-
	<u>4,834,501</u>	<u>7,633,767</u>
Less: Allowance for credit loss (refer note 26)	(17,067)	-
	<u>4,817,434</u>	<u>7,633,767</u>

The Company's exposure to credit and currency risks and allowances for credit loss related to trade receivables are disclosed in note 26.

Trade receivables ageing schedule

As at 31 March 2022

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Undisputed						
Trade receivables considered good	4,662,967	34,323	40,637	24,461	55,046	4,817,434
Trade receivables which have significant increase in credit risk	-	-	-	-	17,067	17,067
Trade receivables - credit impaired	-	-	-	-	-	-
Disputed						
Trade receivables considered good	-	-	-	-	-	-
Trade receivables which have significant increase in credit risk	-	-	-	-	-	-
Trade receivables - credit impaired	-	-	-	-	-	-
Total	4,662,967	34,323	40,637	24,461	72,113	4,834,501

As at 31 March 2021

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months to 1 year	1 to 2 years	2 to 3 years	More than 3 years	
Undisputed						
Trade receivables considered good	6,918,972	9,796	602,648	85,284	17,067	7,633,767
Trade receivables which have significant increase in credit risk	-	-	-	-	-	-
Trade receivables - credit impaired	-	-	-	-	-	-
Disputed						
Trade receivables considered good	-	-	-	-	-	-
Trade receivables which have significant increase in credit risk	-	-	-	-	-	-
Trade receivables - credit impaired	-	-	-	-	-	-
Total	6,918,972	9,796	602,648	85,284	17,067	7,633,767

	As at 31 March 2022	As at 31 March 2021
8 Cash and cash equivalents		
Balances with banks in current accounts	532,607	425,904
	<u>532,607</u>	<u>425,904</u>



SFS Pharma Logistics Private Limited
Notes to the financial statements for the year ended 31 March 2022 (Continued)
(All amounts in Indian rupees)

	As at 31 March 2022	As at 31 March 2021
9 Equity share capital		
Authorised capital		
10,00,000 (31 March 2021 - 10,00,000) equity shares of ₹ 10 each	10,00,000	10,00,000
	<u>10,00,000</u>	<u>10,00,000</u>
Issued, subscribed and paid-up capital		
10,00,000 (31 March 2021 - 10,00,000) equity shares of ₹ 10 each	10,00,000	10,00,000
	<u>10,00,000</u>	<u>10,00,000</u>

a. Reconciliation of the number of equity shares outstanding at the beginning and at the end of the reporting year is as given below:

Particulars	As at 31 March 2022		As at 31 March 2021	
	No. of shares	Amount	No. of shares	Amount
Shares at the beginning of the year	1,000,000	10,00,000	1,000,000	10,00,000
Issued during the year	-	-	-	-
Number of shares at the end of the year	1,000,000	10,00,000	1,000,000	10,00,000

b. Rights, preferences and restrictions attached to equity shares

The Company has only one class of equity shares having a par value of ₹ 10/- per share. Each holder of the equity shares is entitled to one vote per share.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by shareholders.

c. Details of equity shares held by shareholders holding more than 5% of the aggregate shares in the Company

Particulars	As at 31 March 2022		As at 31 March 2021	
	No. of shares	% holding	No. of shares	% holding
M/s Aspinwall and Company Limited	1,000,000	100%	1,000,000	100%
	<u>1,000,000</u>	<u>100%</u>	<u>1,000,000</u>	<u>100%</u>

d. Details of equity shares held by promoters

Particulars	As at 31 March 2022		As at 31 March 2021	
	No. of shares	% holding	No. of shares	% holding
M/s Aspinwall and Company Limited	1,000,000	100%	1,000,000	100%
	<u>1,000,000</u>	<u>100%</u>	<u>1,000,000</u>	<u>100%</u>

Note

There are no changes in the shareholding of promoters during the current year as compared to the previous year.

e. Details of buyback, bonus shares, issue for consideration other than for cash for past 5 years

There were no shares allotted as fully paid up by way of bonus shares, shares issued for consideration other than for cash and shares bought back during the 5 years immediately preceding the balance sheet date.

f. All the 10,00,000 (31 March 2021 - 10,00,000) equity shares are held by the holding company - M/s Aspinwall and Company Limited and its nominees.



	As at 31 March 2022	As at 31 March 2021
10 Provisions		
Non-current		
Provision for employee benefits		
- Gratuity	512,110	351,840
- Compensated absences	270,696	155,640
	<u>782,806</u>	<u>507,480</u>
Current		
Provision for employee benefits		
- Gratuity	58,000	42,000
- Compensated absences	49,000	30,000
	<u>107,000</u>	<u>72,000</u>

11 Borrowings		
Current		
<i>Unsecured</i>		
Loan from holding company (refer note 22)	1,300,000	3,700,000
	<u>1,300,000</u>	<u>3,700,000</u>

Details of securities, terms and conditions on borrowings

Loan from holding company (Aspinwall and Company Limited) is unsecured and is repayable within a period of 1 years from the balance sheet date and carry interest rate @ 10% p.a (Previous year - 10% p.a)

12 Trade payables		
Current		
Dues of micro enterprises and small enterprises (refer note 23)	-	-
Dues of other than micro enterprises and small enterprises	4,611,199	6,988,216
	<u>4,611,199</u>	<u>6,988,216</u>

The Company's exposure to liquidity risks related to trade payables is disclosed in note 26.

Trade payables ageing schedule

As at 31 March 2022

Particulars	Outstanding for following periods from the date of transaction				
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total
Undisputed					
MSME	-	-	-	-	-
Others	4,598,985	12,214	-	-	4,611,199
Disputed					
MSME	-	-	-	-	-
Others	-	-	-	-	-
Total	<u>4,598,985</u>	<u>12,214</u>	<u>-</u>	<u>-</u>	<u>4,611,199</u>

As at 31 March 2021

Particulars	Outstanding for following periods from the date of transaction				
	Less than 1 year	1 to 2 years	2 to 3 years	More than 3 years	Total
Undisputed					
MSME	-	-	-	-	-
Others	6,934,788	-	53,428	-	6,988,216
Disputed					
MSME	-	-	-	-	-
Others	-	-	-	-	-
Total	<u>6,934,788</u>	<u>-</u>	<u>53,428</u>	<u>-</u>	<u>6,988,216</u>

	As at 31 March 2022	As at 31 March 2021
13 Other financial liabilities		
Current		
Contractually reimbursable expenses/ liabilities *	-	3,594,023
Interest accrued but not due on borrowings *	-	309,660
Accrued salaries and benefits	818,490	236,844
Dues to other creditors and accruals	859,411	627,917
	<u>1,677,901</u>	<u>4,768,444</u>

* Includes dues to holding company (refer note 22)

14 Other liabilities		
Current		
Contract liabilities/ Advance from customers	13,116	5,916
Withholding taxes and statutory dues	327,946	127,878
	<u>341,062</u>	<u>133,794</u>



SFS Pharma Logistics Private Limited
Notes to the financial statements for the year ended 31 March 2022 (Continued)
(All amounts in Indian rupees)

	Year ended 31 March 2022	Year ended 31 March 2021
15 Revenue from operations		
<i>Sale of services - Logistics</i>		
Clearing and forwarding	38,575,166	19,363,313
	<u>38,575,166</u>	<u>19,363,313</u>
16 Other income		
Interest income on income-tax refund	11,738	14,519
Other non-operating income		
- Liabilities/ provisions no longer required written back	95,234	13,985
- Miscellaneous income	103	89
	<u>107,075</u>	<u>28,593</u>
17 Employee benefits expense		
Salaries, wages and bonus	4,865,247	3,084,340
Contribution to provident and other funds (refer note 25)	450,913	370,428
Staff welfare expenses	172,474	82,112
	<u>5,488,634</u>	<u>3,536,880</u>
18 Finance costs		
Interest expenses on loan from holding company	355,482	335,479
Interest expenses on delayed payment of statutory dues	5,541	18,450
	<u>361,023</u>	<u>353,929</u>
19 Depreciation expense		
Depreciation on property, plant and equipment	373,775	324,740
	<u>373,775</u>	<u>324,740</u>
20 Other expenses		
Consumption of stores and spares	3,435,491	912,226
Handling expenses	13,859,789	8,362,589
Transporting charges	3,558,813	2,213,165
Power and fuel	377,514	347,132
Rent	1,287,422	1,190,896
Subscription charges	14,939	370,007
Repairs and maintenance		
- Buildings	89,305	75,920
- Others	100,790	61,114
Professional charges	84,437	62,600
Payment to auditors (refer note 20.1 below)	127,500	102,500
Rates and taxes	146,827	83,340
Communication	51,724	65,188
Travelling and conveyance	117,920	48,882
Printing and stationary	27,340	17,420
Exchange loss on currency fluctuations, realised and unrealised (net)	423,722	44,952
Loss on sale of property, plant and equipment (net)	-	4,418
Net impairment loss on financial and contract assets	69,848	-
Provision for obsolescence of inventory	300,000	-
Miscellaneous expenses	207,399	182,656
	<u>24,280,780</u>	<u>14,145,005</u>

Note 20.1 - Payment to auditors (net of goods and services tax) includes following:

As auditor		
- Statutory audit	90,000	75,000
- Other services	32,500	22,500
For reimbursement of expenses	5,000	5,000
	<u>127,500</u>	<u>102,500</u>



21 Earnings per share ("EPS")

The calculation of profit attributable to equity share holders and weighted average number of equity shares outstanding for the purpose of basic earnings per share calculations are as follows:

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
Net profit for the year attributable to the equity shareholders	7,385,850	1,037,476
Weighted average number of equity shares	1,000,000	1,000,000
Par value per share (₹)	10	10
Earning per share - basic and diluted	7.39	1.04

Note: There are no dilutive potential equity shares outstanding during the current year and previous year.

22 Related parties

A. Related party relationships

Names of related parties and description of relationship with the Company:

(a) Holding Company	Aspinwall and Company Limited
(b) Fellow Subsidiaries	a) Aspinwall Technologies Limited b) Aspinwall Geotech Limited c) Aspinwall Healthcare Private Limited d) Malabar Coast Marine Services Private Limited
(c) Non-executive directors	a) Mr. Rama Varma b) Mr. Rajesh S c) Mr. Mohan Kurian

Note: Related parties have been identified by the management and relied upon by the auditors

B. Related party transactions

Nature of transaction	Name of the related party	Year ended 31 March 2022	Year ended 31 March 2021
Receipt of services	Aspinwall and Company Limited	5,701,760	1,948,354
Interest expense	Aspinwall and Company Limited	355,482	335,479
Recoverable expenses incurred by holding company on behalf of Company	Aspinwall and Company Limited	438,275	362,747
Receipt of loan	Aspinwall and Company Limited	-	500,000
Repayment of loan availed	Aspinwall and Company Limited	2,400,000	-

C. The Company has the following balances with related parties:

Nature of transaction	Name of the related party	As at 31 March 2022	As at 31 March 2021
Loan from related parties	Aspinwall and Company Limited	1,300,000	3,700,000
Trade payables	Aspinwall and Company Limited	296,768	1,251,887
Expense reimbursements by the holding company on behalf of the Company	Aspinwall and Company Limited	9,290	4,367,112
Interest accrued on loan availed	Aspinwall and Company Limited	-	309,660

All related party transactions entered during the year were in ordinary course of business and are on arm's length basis.



23 Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006, (MSMED Act)

The information as required under the MSMED Act, 2006 has been determined to the extent such parties have been identified on the basis of information available with the Company and has been relied upon by the auditors.

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
(i) The principal amount remaining unpaid to any supplier as at the end of each accounting year.	-	-
(ii) Interest due thereon remaining unpaid to any supplier as at the end of the accounting year.	-	-
(iii) The amount of interest paid by the buyer in terms of Section 16 of the MSMED Act, 2006 along with the amount of the payment made to the supplier beyond the appointed day during each accounting year.	-	-
(iv) The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act.	-	-
(v) The amount of interest accrued and remaining unpaid at the end of the accounting year.	-	-
(vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23.	-	-

24 Tax assets, liabilities and reconciliations

A. Deferred tax (asset)/ liabilities

(a) Movement in deferred tax balances for the year ended 31 March 2022

	Balance as at 1 April 2021	Recognised in profit or loss	Recognised in OCI	As at 31 March 2022		
				Net	Deferred tax asset	Deferred tax liability
Employee benefits *	(140,062)	(59,691)	(20,995)	(220,748)	220,748	-
Property, plant and equipment	142,855	3,481	-	146,336	-	146,336
Net deferred tax	2,793	(56,210)	(20,995)	(74,412)	220,748	146,336

(b) Movement in deferred tax balances for the year ended 31 March 2021

	Balance as at 1 April 2020	Recognised in profit or loss	Recognised in OCI	As at 31 March 2021		
				Net	Deferred tax asset	Deferred tax liability
Employee benefits *	(136,104)	(15,473)	11,515	(140,062)	140,062	-
Property, plant and equipment	133,506	9,349	-	142,855	-	142,855
Net deferred tax	(2,598)	(6,124)	11,515	2,793	140,062	142,855

* Includes provision for gratuity, provision for leave encashment and actuarial gain/ loss on remeasurement of defined benefit liability recognised in other comprehensive income.

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority.

B. Income tax assets/ (liabilities)

Particulars	As at 31 March 2022	As at 31 March 2021
Non-current		
Advance tax, net of provision for tax:	684,573	375,458
	684,573	375,458

C. Amount recognised in statement of profit and loss

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
Current tax	1,235,615	117,537
MAT credit utilised	(387,226)	(117,537)
Deferred tax (credit)/ charge	(56,210)	(6,124)
Net tax expense	792,179	(6,124)

D. Amount recognised in other comprehensive income

Particulars	Before tax	Tax expense	Net of tax
Year ended 31 March 2022			
Remeasurement of defined benefit liability	80,750	(20,995)	59,755
	80,750	(20,995)	59,755
Year ended 31 March 2021			
Remeasurement of defined benefit liability	(44,290)	11,515	(32,775)
	(44,290)	11,515	(32,775)



24 Tax assets, liabilities and reconciliations (Continued)

E. Reconciliation of effective tax rate

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
Profit before tax	8,178,029	1,031,352
Company's domestic tax rate	26%	26%
Tax using Company's domestic tax rate	2,126,288	268,151
Impact of:		
Timing difference on account employee benefits expenses and depreciation	(56,210)	(6,124)
Set off brought forward losses against profits for the year	(1,277,899)	(268,151)
Income tax expense	792,179	(6,124)

The tax rate used for reconciliation above is the corporate tax rate of 26% payable by corporate entities in India on taxable profits under Indian tax law.

25 Employee benefits

I. The employee benefit schemes are as under:

(a) Defined contribution plan

The Company makes contributions towards provident fund for qualifying employees. An amount of ₹ 2,47,506 (31 March 2021 - ₹ 2,04,705) has been recognised and included in 'Contribution to provident and other funds' in the statement of profit and loss on account of provident fund.

The Company has recognised ₹ 1,07,887 (31 March 2021: ₹ 83,263) for superannuation contribution in the standalone statement of profit and loss.

(b) Defined benefit plan

The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of service gets a gratuity on death or resignation or retirement at 15 days salary (last drawn salary) for each completed year of service. The scheme is unfunded and an amount of ₹ 95,520 (31 March 2021: ₹ 82,460) has been recognised and included in "Contribution to provident and other funds" in the statement of profit and loss on account of provision.

II. The following tables sets out the particulars of the employee benefits as required under the Ind AS 19-"Employee Benefits".

i) The amounts recognised in the balance sheet and the movements in the defined benefit obligation over the year for Gratuity are as follows:

Particulars	As at 31 March 2022		As at 31 March 2021	
	Present value of obligation	Net defined benefit liability	Present value of obligation	Net defined benefit liability
Opening balance	393,840	393,840	355,670	355,670
Current service cost	72,280	72,280	60,760	60,760
Interest costs	23,240	54,190	21,700	21,700
Total amount recognised in profit and loss	95,520	126,470	82,460	82,460
Remeasurements				
(Gain)/ loss from change in financial assumptions	(12,840)	(12,840)	(50,080)	(50,080)
Experience (gains)/ losses	93,590	93,590	5,790	5,790
Total amount recognised in other comprehensive income	80,750	80,750	(44,290)	(44,290)
Benefits paid	-	-	-	-
Closing balance	570,110	601,060	393,840	393,840

ii) Actuarial assumptions:

The following were the principal actuarial assumptions at the reporting date (expressed as weighted averages):

Particulars	Gratuity		Compensated absences	
	31 March 2022	31 March 2021	31 March 2022	31 March 2021
Discount rate	6.20%	5.90%	6.20%	5.90%
Salary escalation rate (p.a)	8%	8%	8%	8%
Attrition rate	12%	12%	12%	12%

Discount rate: The discount rate indicated above reflects the estimated timing and currency of benefit payments. It is based on the yields/ rates available on applicable bonds as on the current valuation date.

Salary escalation rate: The salary growth rate indicated above is the Company's best estimate of an increase in salary of the employees in future years, determined considering the general trend in inflation, seniority, promotions, past experience and other relevant factors such as demand and supply in employment market, etc.

Attrition rate: Attrition rate indicated above represents the Group's best estimate of employee turnover in future (other than on account of retirement, death or disablement) determined considering various factors such as nature of business, retention policy, industry factors, past experience, etc.



25 Employee benefits (Continued)

iii) Sensitivity analysis

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown below.

	31 March 2022		31 March 2021	
	Increase	Decrease	Increase	Decrease
Effect of 1% change in the assumed discount rate	(39,350)	44,870	(27,500)	31,390
Effect of 1% change in the assumed salary growth rate	43,740	(39,150)	30,510	(27,290)
Effect of 1% change in the assumed attrition rate	(6,630)	7,270	(4,860)	5,360

Although the analysis does not take account of the full distribution of cash flows expected under the plan, it does provide an approximation of the sensitivity of the assumptions shown.

iv) Maturity profile of defined benefit obligation

Expected cash flows

	Gratuity	
	31 March 2022	31 March 2021
Year 1	60,250	42,990
Year 2	62,840	45,330
Year 3	65,020	47,300
Year 4	86,250	48,960
Year 5	96,150	70,390
Year 6 to 10	583,330	409,820

As at 31 March 2022, the weighted average duration of the defined benefit obligation was 5 years.

26 Financial instruments - fair values and risk management

A Accounting classifications and fair values*

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

31 March 2022

Particulars	Carrying value			Fair value			
	Amortised cost	Financial assets/liabilities at FVTPL	Total	Level 1	Level 2	Level 3	Total
Financial assets not measured at fair value							
Trade receivables	4,817,434	-	4,817,434	-	-	-	-
Cash and cash equivalents	532,607	-	532,607	-	-	-	-
Other financial assets	4,443,464	-	4,443,464	-	-	-	-
	9,793,505	-	9,793,505	-	-	-	-
Financial liabilities not measured at fair value							
Borrowings	1,300,000	-	1,300,000	-	-	-	-
Trade payables	4,611,199	-	4,611,199	-	-	-	-
Other financial liabilities	1,677,901	-	1,677,901	-	-	-	-
	7,589,100	-	7,589,100	-	-	-	-

31 March 2021

Particulars	Carrying value			Fair value			
	Amortised cost	Financial assets/liabilities at FVTPL	Total	Level 1	Level 2	Level 3	Total
Financial assets not measured at fair value							
Trade receivables	7,633,767	-	7,633,767	-	-	-	-
Cash and cash equivalents	425,904	-	425,904	-	-	-	-
Other financial assets	4,458,469	-	4,458,469	-	-	-	-
	12,518,140	-	12,518,140	-	-	-	-
Financial liabilities not measured at fair value							
Borrowings	3,700,000	-	3,700,000	-	-	-	-
Trade payables	6,988,216	-	6,988,216	-	-	-	-
Other financial liabilities	4,768,444	-	4,768,444	-	-	-	-
	15,456,660	-	15,456,660	-	-	-	-

* The fair value of trade receivables, cash and cash equivalents, other financial assets, borrowings, trade payables and other financial liabilities approximate their carrying amount largely due to short-term nature of these instruments.



26 Financial instruments (continued)

B Capital management

The key objective of the Company's capital management is to ensure that it maintains a stable capital structure with the focus on total equity to uphold investor, creditor and customer confidence and to ensure future developments of the business. The Company is focused on maintaining a strong equity base to ensure independence, security as well as financial flexibility for potential future borrowings, if required, without impacting the risk profile of the Company.

The Company's debt to equity ratio at the reporting date are as follows:

Particulars	As at 31 March 2022	As at 31 March 2021
Total liabilities	8,819,968	16,172,727
Less: Cash and cash equivalents	(532,607)	(425,904)
Net debt (A)	8,287,361	15,746,823
Total equity (B)	8,425,856	1,099,761
Debt to equity ratio (A/B)	0.98	14.32

There are no changes in the Company's approach to capital management during the year. The Company is not subject to externally imposed capital requirements.

C Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- (i) Credit risk;
- (ii) Liquidity risk; and
- (iii) Market risk

Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The board of directors is responsible for developing and monitoring the Company's risk management policies.

The Company's risk management policies are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

The Board of directors oversee how management monitors compliance with the Company's risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company.

(i) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investments in liquid mutual funds.

The carrying amount of following financial assets represents the maximum credit exposure.

Trade receivables

The Company's exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk of the industry.

Credit risk has always been managed by the Company through credit approvals, establishing credit limits and continuously monitoring the credit worthiness of customers based on which the Company agrees on the credit terms with customers in the normal course of business. On account of adoption of Ind AS 109, the Company uses expected credit loss model to assess the impairment loss or gain. The Company uses a provision matrix to compute the expected credit loss allowance for trade receivables and unbilled revenue. The provision matrix takes into account available external and internal credit risk factors and the Company's historical experience for customers.

The movement in allowance for credit loss in respect of trade receivables during the year was as follows:

Allowance for credit loss	As at 31 March 2022	As at 31 March 2021
Balance at the beginning	-	-
Impairment loss recognised	69,848	-
Amounts written off	(22,112)	-
Balance at the end	47,736	-



26 Financial instruments (continued)

C Financial risk management (Continued)

(ii) Liquidity risk

Liquidity risk is the risk that the Company will encounter in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach for managing liquidity is by ensuring, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company's objective is to maintain a balance between continuity of funding and flexibility through the use of bank facilities and by ensuring adequate internally generated funds.

Exposure to liquidity risk

The contractual undiscounted cash flows associated with financial liabilities at reporting dates are as follows:

31 March 2022	Carrying amount	Total	Contractual cash flows			
			Less than one year	1-2 years	2-5 years	More than 5 years
Financial liabilities						
Borrowings	1,300,000	1,300,000	1,300,000	-	-	-
Trade payables	4,611,199	4,611,199	4,611,199	-	-	-
Other financial liabilities	1,677,901	1,677,901	1,677,901	-	-	-
	7,589,100	7,589,100	7,589,100	-	-	-

31 March 2021	Carrying amount	Total	Contractual cash flows			
			Less than one year	1-2 years	2-5 years	More than 5 years
Financial liabilities						
Borrowings	3,700,000	3,700,000	3,700,000	-	-	-
Trade payables	6,988,216	6,988,216	6,988,216	-	-	-
Other financial liabilities	4,768,444	4,768,444	4,768,444	-	-	-
	15,456,660	15,456,660	15,456,660	-	-	-

The gross (inflows)/ outflows disclosed in the above table represent the contractual undiscounted cash flows relating to financial liabilities.

(iii) Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates and interest rates which will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimising the return.

As of now, the Company has not entered into any sort of derivative contracts, in order to manage market risks.

(a) Foreign currency risk

The Company is exposed to currency risk to the extent that there is a mismatch between the currencies in which transactions are denominated and the functional currency of the Company. The functional currency of company is INR. The currencies in which these transactions are primarily denominated are USD, GBP, EURO, CAD, AUD and SGD.

The summary quantitative data about the Company's exposure to currency risk at the end of reporting period expressed in INR are as follows:

As at 31 March 2022

Particulars	USD	GBP	EURO	CAD	AUD	SGD
Financial assets						
Trade receivables	6,066,277	1,548,186	-	-	-	-
Other financial assets	494,650	-	-	-	-	-
Net exposure to foreign currency risk (assets)	6,470,927	1,548,186	-	-	-	-
Financial liabilities						
Trade payables	625,970	154,154	203,668	-	-	-
Net exposure to foreign currency risk (liabilities)	625,970	154,154	203,668	-	-	-

As at 31 March 2021

Particulars	USD	GBP	EURO	CAD	AUD	SGD
Financial assets						
Trade receivables	5,558,180	1,353,392	-	-	253,552	202,347
Other financial assets	447,504	-	-	-	-	-
Net exposure to foreign currency risk (assets)	6,005,684	1,353,392	-	-	253,552	202,347
Financial liabilities						
Trade payables	647,385	306,729	1,111,737	34,932	-	-
Net exposure to foreign currency risk (liabilities)	647,385	306,729	1,111,737	34,932	-	-



26 Financial instruments (continued)

C Financial risk management (Continued)

(iii) Market risk (Continued)

(a) Foreign currency risk (Continued)

Sensitivity analysis

Particulars	Impact on profit or (loss)		Impact on equity, net of tax	
	As at 31 March 2022	As at 31 March 2021	As at 31 March 2022	As at 31 March 2021
USD sensitivity				
INR/USD - increase by 1%	58,450	53,583	43,253	45,224
INR/USD - decrease by 1%	(58,450)	(53,583)	(43,253)	(45,224)
GBP sensitivity				
INR/GBP - increase by 1%	13,940	10,467	10,316	8,834
INR/GBP - decrease by 1%	(13,940)	(10,467)	(10,316)	(8,834)
EURO sensitivity				
INR/EURO - increase by 1%	(2,037)	(11,117)	(1,507)	(9,383)
INR/EURO - decrease by 1%	2,037	11,117	1,507	9,383
CAD sensitivity				
INR/CAD - increase by 1%	-	(349)	-	(295)
INR/CAD - decrease by 1%	-	349	-	295
AUD sensitivity				
INR/AUD - increase by 1%	-	2,536	-	2,140
INR/AUD - decrease by 1%	-	(2,536)	-	(2,140)
SGD sensitivity				
INR/SGD - increase by 1%	-	2,023	-	1,707
INR/SGD - decrease by 1%	-	(2,023)	-	(1,707)

I. Assets

Particulars	Foreign currency	As at 31 March 2022			As at 31 March 2021		
		Exchange rate	Amount in foreign currency	Amount in INR	Exchange rate	Amount in foreign currency	Amount in INR
Unhedged	USD	75.30	85,935	6,470,927	73.04	82,222	6,005,684
	GBP	98.36	15,740	1,548,186	99.88	13,550	1,353,392
	AUD	-	-	-	55.24	4,590	253,552
	SGD	-	-	-	53.92	3,753	202,347

II. Liabilities

Particulars	Foreign currency	As at 31 March 2022			As at 31 March 2021		
		Exchange rate	Amount in foreign currency	Amount in INR	Exchange rate	Amount in foreign currency	Amount in INR
Unhedged	USD	76.11	8,225	625,970	73.86	8,765	647,385
	GBP	100.17	1,539	154,154	101.76	3,014	306,729
	EURO	85.11	2,393	203,668	86.63	12,834	1,111,737
	CAD	-	-	-	58.71	595	34,932

(b) Interest rate risk

The Company's exposure to the risk of changes in market interest rates relates to debt availed from holding company.



27 Disclosure of ratios

Sl. No.	Particulars	Numerator	Denominator	31 March 2022	31 March 2021	% of change	Explanation for change more than 25%
1	Current Ratio - times	Current Assets	Current liabilities	1.68	0.91	85%	The increase is on account of higher efficiency on working capital.
2	Debt-Equity Ratio	Total debt less Cash and Cash equivalents	Share holders Equity	0.98	14.32	93%	The variation is on account of reduction in debt and increase in equity as at 31 March 2022 on account of repayment of dues to holding company and revenue growth during the year.
3	Return on Equity Ratio - in %	Net profit after Tax	Average Share holders Equity	38.77%	45.66%	15%	Not applicable
4	Trade Receivables turnover ratio	Revenue	Trade receivables	8.01	2.34	216%	On account of growth in revenue and with reduction in receivables.
5	Trade payables turnover ratio	Purchase of service and expenses	Trade payables	6.01	2.48	142%	On account of growth in business and decrease in trade payables.
6	Net capital turnover ratio	Revenue	Working Capital	7.07	(13.50)	152%	Variation is on account of growth in revenue and increase in working capital for the year.
7	Net profit ratio - in %	Net profit after Tax	Revenue	19.09%	5.35%	257%	On account of growth in revenue and corresponding increase in profit.
8	Return on Capital employed - in %	Earnings before interest and taxes	Equity and debt	87.80%	28.86%	204%	On account of growth in business and profit for the year and part repayment of loan



SFS Pharma Logistics Private Limited

Notes to the financial statements for the year ended 31 March 2022 (Continued)

(All amounts in Indian rupees)

28 Impact of COVID-19

COVID-19 outbreak was declared as a global pandemic by World Health Organization. The Company has kept its operations continuously in compliance with the directives issued by the Government authorities. Accordingly, as on 31 March 2022, based on facts and circumstances existing as of that date, the Company does not anticipate any material uncertainty which affects its liquidity position and also ability to continue as a going concern. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration.

29 As at 31 March 2022 and 31 March 2021, the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

30 Previous year figures have been regrouped/reclassified wherever necessary to conform to the current year's presentation.

As per our report of even date attached.

for **JERRY, SUNNY & RAJESH**

Chartered Accountants

ICAI Firm Registration number: 001326S



Sunny Varghese

Partner

Membership No: 028612

Place: Kochi

Date: 10 May 2022



for and on behalf of the Board of Directors of

SFS Pharma Logistics Private Limited

CIN: U63000KL2011PL0020554



Rajesh S

Director

DIN: 00043860

Place: Kochi

Date: 10 May 2022



Mahesh K

Director

DIN: 00360182